Juliet Cunningham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SAN DIEGO, April 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.

QuidelOrtho Corporation misses on earnings expectations. Reported EPS is $1.17 EPS, expectations were $2.02.

Operator: Welcome to the QuidelOrtho Third Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.

SAN DIEGO, CA - September 11, 2023 - QuidelOrtho Corporation , a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and...

Juliet Cunningham: Thank you. Good afternoon, everyone. With me today are Chris Barry, Chief Executive Officer; and Matt Harbaugh, Chief Financial Officer.